Cargando…
SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
Immunotherapeutic strategies including the blockade of programmed death 1 (PD-1) receptors hold promise for the treatment of various cancers including non-small cell lung carcinoma (NSCLC). Preclinical data suggest that pre-existing tumor immunity is important for disease regression upon checkpoint...
Autores principales: | Dhodapkar, Kavita M, Gettinger, Scott N, Das, Rituparna, Zebroski, Henry, Dhodapkar, Madhav V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782159/ https://www.ncbi.nlm.nih.gov/pubmed/24073380 http://dx.doi.org/10.4161/onci.25205 |
Ejemplares similares
-
Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014) -
High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
por: Velcheti, Vamsidhar, et al.
Publicado: (2013) -
Checkpoint Inhibition in Myeloma: Opportunities and Challenges
por: Costa, Federica, et al.
Publicado: (2018) -
Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
por: McCachren, Samuel S., et al.
Publicado: (2021) -
Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
por: Dhodapkar, Madhav V., et al.
Publicado: (2019)